RE:Perspective I understand your point and it is absolutely crazy since they have zero revenues. If those Barclays cancer biotech analyst's peak revenue multiples are to be believed, if just one of the tumor types suceeds in the trial, you'd be close to that level (undiscounted). So maybe in the not to distant future!
I find it hard to think you'd see one out of the 5 work unless there were really odd things going on with the Sortilin expression or tumor microenvironments being vastly different (I guess every tumors environment is diff). Even though the trial is actually for ALL solid tumors with sortilin overexpression, the oncologists will likely use it for those where efficacy was superior to existing approaches. But have to think if it works, it will work in more than one type of tumor given the MOA.
jeffm34 wrote: At its 52 week high CYDY had a $6B valuation. That would be roughly a $60 share price for TH. But let's keep giving management a pass. This time they will figure it out.